Neuroendocrine neoplasms of the gastrointestinal tract;Gastroenteropankreatische neuroendokrine neoplasien

Deutsches Arzteblatt

Volumn 108, Issue 18, 2011, Pages 305-312

  Schott, Matthias ^a   Klöppel, Günter ^b   Raffel, Andreas ^a   Saleh, Andreas ^a   Knoefel, Wolfram Trudo ^a   Scherbaum, Werner A ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; HORMONE; KI 67 ANTIGEN; OCTREOTIDE; SYNAPTOPHYSIN;

CANCER PALLIATIVE THERAPY; CANCER STAGING; CELL PROLIFERATION; CHEMOEMBOLIZATION; DIGESTIVE SYSTEM CANCER; GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASM; HORMONE SYNTHESIS; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; RADICAL RESECTION; RADIOFREQUENCY ABLATION; REVIEW; SCINTIGRAPHY; TISSUE DIFFERENTIATION; TUMOR VOLUME;

GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS;

EID: 79959466794     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2011.0305     Document Type: Review

References (26)

1. Modlin IM, Oberg K, Chung DC, et al.: Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol 2008; 9: 61-72.
2. Garbrecht N, Anlauf M, Schmitt A, et al.: Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15: 229-41. (Pubitemid 351449742)
3. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA: Factors associated with progression of carcinoid heart disease. N Engl J Med 2003; 348: 1005-15. (Pubitemid 36302245)
4. Williams ED, Sandler M: The classification of carcinoid tumors. Lancet 1963; 1(7275): 238-9.
5. Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P: Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451(Suppl 1): 9-27.
6. Rindi G, Arnold R, Bosman FT, et al.: Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds.) WHO classification of tumors of the digestive system. Lyon: IARC 2010.
7. Rindi G, Kloppel G, Couvelard A, et al.: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-62. (Pubitemid 47497934)
8. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994-1006. (Pubitemid 23090750)
9. O'Toole D, Grossman A, Gross D, et al.: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202.
10. Raffel A, Krausch MM, Anlauf M, et al.: Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery 2007; 141: 179-84. (Pubitemid 46157250)
11. Sundin A, Vullierme MP, Kaltsas G, Plockinger U: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-83.
12. Dromain C, de BT, Lumbroso J, et al.: Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23: 70-8. (Pubitemid 41702624)
13. Buchmann I, Henze M, Engelbrecht S, et al.: Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-26. (Pubitemid 47476920)
14. Tonelli F, Fratini G, Nesi G, et al.: Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006; 244: 61-70. (Pubitemid 44297449)
15. Anlauf M, Garbrecht N, Henopp T, et al.: Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinicopathological and epidemiological features. World J Gastroenterol 2006; 12: 5440-6. (Pubitemid 44501800)
16. Anlauf M, Bauersfeld J, Raffel A, et al.: Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol 2009; 33: 339-46.
17. Marrache F, Vullierme MP, Roy C, et al.: Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumors. Br J Cancer 2007; 96: 49-55. (Pubitemid 46094638)
18. Mazzaglia PJ, Berber E, Milas M, Siperstein AE: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142: 10-19. (Pubitemid 47042092)
19. Rinke A, Muller HH, Schade-Brittinger C, et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.
20. Plockinger U, Rindi G, Arnold R, et al.: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424.
21. Eriksson B, Annibale B, Bajetta E, et al.: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009; 90: 214-9.
22. Eriksson B, Kloppel G, Krenning E, et al.: Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8-19. (Pubitemid 350308290)
23. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al.: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-6.
24. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al.: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-62. (Pubitemid 46179465)
25. Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-30.
26. Pape UF, Berndt U, Muller-Nordhorn J, et al.: Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2008; 15: 1083-97.